Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases
- PMID: 3719098
Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases
Abstract
One hundred sixty-eight patients with primary systemic amyloidosis (AL) were identified. Median survival after diagnosis was 12 months and ranged from 4 months for patients presenting with congestive heart failure to 50 months for those presenting with peripheral neuropathy only. Utilizing the proportional-hazards model in a stepwise multivariate fashion to evaluate the simultaneous influence of putative risk factors as of diagnosis revealed that congestive heart failure, urine light chain, hepatomegaly, and multiple myeloma were the major factors adversely affecting survival during the first year after diagnosis. Serum creatinine, multiple myeloma, orthostatic hypotension, and monoclonal serum protein were the most important variables adversely affecting survival for patients surviving 1 year. These models were used to categorize patients according to the variables in the models into low-, moderate-, and high-risk groups for the first year after diagnosis and separately for subsequent years. The influence of these variables on survival is important in stratification of patients randomized to prospective clinical trials.
Similar articles
-
Primary systemic amyloidosis--a diagnostic primer.Mayo Clin Proc. 1989 Dec;64(12):1505-19. doi: 10.1016/s0025-6196(12)65706-1. Mayo Clin Proc. 1989. PMID: 2513459 Review.
-
Hepatic amyloidosis (primary [AL], immunoglobulin light chain): the natural history in 80 patients.Am J Med. 1988 Jul;85(1):73-80. doi: 10.1016/0002-9343(88)90505-0. Am J Med. 1988. PMID: 3389383
-
Long-term survival (10 years or more) in 30 patients with primary amyloidosis.Blood. 1999 Feb 1;93(3):1062-6. Blood. 1999. PMID: 9920856 Review.
-
Amyloidosis (AL). Clinical and laboratory features in 229 cases.Mayo Clin Proc. 1983 Oct;58(10):665-83. Mayo Clin Proc. 1983. PMID: 6353084 Review.
-
Amyloidosis: review of 236 cases.Medicine (Baltimore). 1975 Jul;54(4):271-99. doi: 10.1097/00005792-197507000-00001. Medicine (Baltimore). 1975. PMID: 1152671
Cited by
-
Novel pharmacotherapies for cardiac amyloidosis.Pharmacol Ther. 2017 Dec;180:129-138. doi: 10.1016/j.pharmthera.2017.06.011. Epub 2017 Jun 22. Pharmacol Ther. 2017. PMID: 28648829 Free PMC article. Review.
-
Echocardiographic findings of patients with transthyretin amyloid cardiomyopathy.J Echocardiogr. 2025 Mar;23(1):1-9. doi: 10.1007/s12574-024-00672-w. Epub 2024 Dec 27. J Echocardiogr. 2025. PMID: 39729212 Review.
-
A new staging system using right atrial strain in patients with immunoglobulin light-chain cardiac amyloidosis.ESC Heart Fail. 2024 Jun;11(3):1612-1624. doi: 10.1002/ehf2.14710. Epub 2024 Feb 23. ESC Heart Fail. 2024. PMID: 38400613 Free PMC article.
-
Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis.Med Oncol. 1999 Jul;16(2):104-9. doi: 10.1007/BF02785843. Med Oncol. 1999. PMID: 10456658 Clinical Trial.
-
Immunoglobulin Light-Chain Amyloidosis: Clinical Presentations and Diagnostic Approach.J Adv Pract Oncol. 2019 Jul;10(5):470-481. doi: 10.6004/jadpro.2019.10.5.5. Epub 2019 Jul 1. J Adv Pract Oncol. 2019. PMID: 33457060 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical